Transgenic mouse models of human breast cancer

被引:104
作者
Hutchinson, JN
Muller, WJ
机构
[1] McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada
[2] McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada
[3] McMaster Univ, Dept Biochem, Hamilton, ON L8S 4K1, Canada
[4] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada
关键词
transgenic mice; knockout mice; mammary gland; cancer; oncogenes; tumor suppressors;
D O I
10.1038/sj.onc.1203970
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The pathogenesis of human breast cancer is thought to involve multiple genetic events, the majority of which fall into two categories, gain of function mutations in protooncogenes such as c-myc, cyclin D1, ErbB-2 and various growth factors which are involved in supporting cell growth, division and survival, and loss of function mutations in so called 'tumor suppressor' genes, such as p53, which are involved in preventing unrestrained cellular growth. A number of mouse systems exist to address the significance of these mutations in the pathogenesis of breast cancer including transgenic mice expressing high levels of a specific gene in target tissues and knockout mice in which specific genes have been ablated via homologous recombination. More recently, the:combination of these techniques to create bigenics as well as the use of 'knockin' and conditional tissue specific gene targeting strategies have allowed the models more reflective of the human disease to be devised. Studies with these models have not only implicated particular genetic events in the progression of the disease but have emphasized the complex, multi-step nature of breast cancer progression. These models also provide the opportunity to study various aspects of the pathogenesis of this disease, from hormonal effects to responses to chemotherapeutic drugs. It is hoped that through the combined use of these models, and the further development of more relevant models, that a deeper understanding of this disease and the generation of new therapeutic agents will result.
引用
收藏
页码:6130 / 6137
页数:8
相关论文
共 97 条
[41]  
Kitsberg DI, 1996, ONCOGENE, V13, P2507
[42]  
Krane IM, 1996, ONCOGENE, V12, P1781
[43]  
Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO
[44]  
2-O
[45]  
Lamszus K, 1997, LAB INVEST, V76, P339
[46]   CONSEQUENCES OF WIDESPREAD DEREGULATION OF THE C-MYC GENE IN TRANSGENIC MICE - MULTIPLE NEOPLASMS AND NORMAL DEVELOPMENT [J].
LEDER, A ;
PATTENGALE, PK ;
KUO, A ;
STEWART, TA ;
LEDER, P .
CELL, 1986, 45 (04) :485-495
[47]   Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway [J].
Lee, RJ ;
Albanese, C ;
Fu, MF ;
D'Amico, M ;
Lin, B ;
Watanabe, G ;
Haines, GK ;
Siegel, PM ;
Hung, MC ;
Yarden, Y ;
Horowitz, JM ;
Muller, WJ ;
Pestell, RG .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (02) :672-683
[48]   pp60v-src induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways -: A role for cAMP response element-binding protein and activating transcription factor-2 in pp60v-src signaling in breast cancer cells [J].
Lee, RJ ;
Albanese, C ;
Stenger, RJ ;
Watanabe, G ;
Inghirami, G ;
Haines, GK ;
Webster, M ;
Muller, WJ ;
Brugge, JS ;
Davis, RJ ;
Pestell, RG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (11) :7341-7350
[49]  
LEMOINE NR, 1990, ONCOGENE, V5, P237
[50]   neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice [J].
Li, BL ;
Rosen, JM ;
McMenaminBalano, J ;
Muller, WJ ;
Perkins, AS .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (06) :3155-3163